AcuCort AB (publ) (XSAT:ACUC)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.684
-0.014 (-2.01%)
At close: Feb 27, 2026
-12.53%
Market Cap 160.36M
Revenue (ttm) 6.68M
Net Income (ttm) -26.19M
Shares Out 234.44M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 403,005
Average Volume 912,125
Open 0.725
Previous Close 0.698
Day's Range 0.665 - 0.725
52-Week Range 0.500 - 0.970
Beta 1.52
RSI 34.43
Earnings Date Feb 20, 2026

About AcuCort AB

AcuCort AB (publ) operates as a pharmaceutical company. It offers Zeqmelit, an oral film containing the glucocorticoid dexamethasone for the treatment of acute allergic reactions, croup in children, nausea and vomiting associated with chemotherapy, and for the treatment of patients with COVID-19 who experience respiratory difficulties and require oxygen therapy. The company was incorporated in 2006 and is based in Lund, Sweden. [Read more]

Industry Pharmaceutical Preparations
Founded 2006
Employees 4
Stock Exchange Spotlight Stock Market
Ticker Symbol ACUC
Full Company Profile

Financial Performance

In 2025, AcuCort AB's revenue was 6.68 million, a decrease of -13.40% compared to the previous year's 7.72 million. Losses were -26.19 million, 50.5% more than in 2024.

Financial Statements

News

There is no news available yet.